Replies to post #17543 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

MNTA has chosen to take the 50%/50% route with CSL for M230.

I'll have to listen to the CC to be able to understand their theory for this action.

Were they obligated to make a decision on this at this point? It seems extremely early to have to decide on this, while the ink of the original contract is barely dry.

Too make this call before any patient has been dosed makes we wonder why they needed to partner this drug for a couple of million dollars if they had that much confidence. On the other hand, Momenta's record of new drug development compares right in line with it's legal wins.

[DewDiligence]

Please see #msg-133516358.